Key result
Treatment with siRNA-4 targeting the viral protease 2A achieved a 92% inhibition of Coxsackievirus B3 replication in vitro, requiring a perfect sequence match in the central region of the viral positive strand.
Why the study?
Does siRNA targeting CVB3 reduce viral replication in in vitro models of viral myocarditis?
Population
HeLa cells and murine cardiomyocytes (HL-1 cell line) infected with Coxsackievirus B3 (CVB3)
Comparison
Transfection with CVB3-specific small… vs Mock transfection, irrelevant siRNA, or lamin…
Design
Preclinical
Follow-up
Up to 48 hours postinfection
Authors
Loading...
Hypothesis-generating for siRNA in viral myocarditis; in vivo studies required before clinical consideration.
Does siRNA targeting CVB3 reduce viral replication in in vitro models of viral myocarditis?
Effect estimate: 92% inhibition
siRNA-4 targeting the viral protease 2A effectively inhibits Coxsackievirus B3 replication in vitro, providing a potential therapeutic target for viral myocarditis.
Ji et al. (2005) studied Coxsackievirus B3 (CVB3) infection. siRNA-4 (targeting viral protease 2A) vs. Irrelevant siRNA (siRNA-C) or mock transfection was evaluated on Inhibition of CVB3 replication (92% inhibition). Treatment with siRNA-4 targeting the viral protease 2A achieved a 92% inhibition of Coxsackievirus B3 replication in vitro, requiring a perfect sequence match in the central region of the viral positive strand.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: